Zyprexa

sales of Excluding the impact of exchange rates, sales of increased 9 percent in the fourth quarter.

For the full year of 2005, worldwide U.S.

Excluding the impact of exchange rates, sales of increased 6 percent in 2005.

Diabetes Care Products In the fourth quarter of 2005, diabetes care revenue, composed primarily of Humalog(R), Humulin(R), Actos(R) and recently launched Byetta, increased 11 percent, to $750.4 million, compared with the fourth quarter of 2004.

Diabetes care revenue increased 17 percent in the U.S., to $434.9 million.

Diabetes care revenue outside the U.S.

increased 5 percent, to $315.5 million.

For the full year of 2005, worldwide diabetes care revenue increased 7 percent, to $2.797 billion.

For the fourth quarter of 2005, worldwide Humalog sales increased 9 percent, to $309.1 million, driven primarily by high...

Lilly incurred the tax on $8 billion in overseas profits returned to the U.S.

Revenue rose to $3.88 billion from $3.64 billion.

Sales of Cymbalta, approved for U.S.

sale in August 2004, more than tripled.

The product is helping Chief Executive Officer Sidney Taurel to compensate for slowing sales of Lilly, which introduced the now-generic Prozac antidepressant in 1986, needs to rebuild its franchise in such central nervous system treatments, said JPMorgan Securities analyst Chris Shibutani in New York.

``Cymbalta has to be successful,'' said Shibutani, who doesn't own the stock, in an interview last week.

``Its importance lies in the expectation that it has blockbuster potential, and it is the most important of the company's new products.'' New drugs including Cymbalta will account for 24 percent of 2006 sales after a projected 18 percent in 2005 and 11 percent the year before, the company said in December.

Beats Expectations Excluding restructuring costs, Lilly said fourth-quarter profit was 80 cents a share, beating the 78 cents estimated b...

Among newer products, sales of Alimta, Byetta, Cialis, Cymbalta, Forteo, Strattera Symbyax, Xigris and Yentreve made up $791.2 million of fourth-quarter sales, or 20% of the total, up from 14% a year ago.

Caterpillar Rolls (TheStreet.com) Baxter Profit Tops Forecast (TheStreet.com) Verizon Hits Targets (TheStreet.com) Microsoft's Zen Moment (TheStreet.com) S&P Testing a Low or Preparing to Bail?

(RealMoney.com) History Repeating (The Trading Reports) A Rock and a Hard Place (The Daily Swing Trade) Key Themes in Telecom (The Telecom Connection) Special After-Hours Update (ActionAlertsPLUS) Chips May Not Stay Down (RealMoney.com) Johnson & Johnson Won't Be Down Long (RealMoney.com) Reality Check on Latin America Investing (RealMoney.com) Favorable Trends (TheStreet.com Stocks Under $10) Trade Triggers (TheStreet.com Technology Report) Earnings May Derail This Stock (Options Alerts) Finding the Good in a Bad Week (Internet Review Weekly Newsletter) Write us!

Order reprints of TSC articles.

Top Investor Relations Contact Us Subscribe to our RSS Feed Subscribe to our PODCAST © 1996- TheStr...